Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation-Reference-Cited by-同舟云学术

Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation

Published:2019-10-19 Issue:4 Volume:107 Page:773-779
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Eichler Hans‐Georg¹²,Koenig Franz²,Arlett Peter¹,Enzmann Harald³⁴,Humphreys Anthony¹,Pétavy Frank¹,Schwarzer‐Daum Brigitte²⁵,Sepodes Bruno⁴⁵⁶,Vamvakas Spiros¹,Rasi Guido¹⁷

Affiliation:

1. European Medicines Agency (EMA) Amsterdam The Netherlands

2. Medical University of Vienna Vienna Austria

3. Federal Institute for Drugs and Medical Devices (BfArM) Bonn Germany

4. EMA's Committee for Medicinal Products for Human Use (CHMP) Amsterdam The Netherlands

5. EMA's Committee for Orphan Medicinal Products (COMP) Amsterdam The Netherlands

6. Universidade de Lisboa Lisbon Portugal

7. University Tor Vergata Rome Italy

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1638

Reference37 articles.

1. Oderkirk J.Readiness of electronic health record systems to contribute to National Health Information and Research. OECD Health Working Papers No. 99 (OECD Publishing Paris France 2017).https://doi.org/10.1787/9e296bf3-en.

2. Real‐World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe

3. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).

4. Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?

5. Real‐World Evidence of Treatment Effects: The Useful and the Misleading

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Examining the Effect of Missing Data and Unmeasured Confounding on External Comparator Studies: Case Studies and Simulations;Drug Safety;2024-08-05

2. Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort study;The Lancet Oncology;2024-08

3. Machine Learning Methods to Estimate Individualized Treatment Effects for Use in Health Technology Assessment;Medical Decision Making;2024-07-26

4. Generating and using real-world data: A worthwhile uphill battle;Cell;2024-03

5. Predicting Individual Treatment Effects: Challenges and Opportunities for Machine Learning and Artificial Intelligence;KI - Künstliche Intelligenz;2024-01-22